Clinical Trials on Haemophilus Influenza

Total 2513 results

Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Seasonal Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Influenza Vaccines

Czech Republic, Estonia, Lithuania
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
The University of Hong Kong

Completed

Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

Influenza A

China
Seoul National University Hospital

Unknown

The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A

H1N1 Influenza

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Orakine Ltd, Dublin, Ireland

Terminated

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer (GP-INFA)

Influenza Infection

France
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Insight Therapeutics, LLC
Brown University; Genentech, Inc.; Case Western Reserve University

Active, not recruiting

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Influenza | Influenza, Human | Influenza -Like Illness

United States
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
University of Leicester
Sanofi Pasteur, a Sanofi Company; University Hospitals, Leicester; World Health... and other collaborators

Completed

Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness (BELIEVE)

Influenza | Influenza -Like Illness

United Kingdom
University of Athens
Hellenic Pasteur Institute

Completed

Influenza Vaccine Effectiveness of a Quadrivalent Vaccine in Pregnant Women and Young Infants, 2019-2020

Influenza in Human

Greece
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
China Academy of Chinese Medical Sciences
Renmin Hospital of Wuhan University; Children's Hospital of Soochow University and other collaborators

Unknown

Clinical Study of Reduning Injection for the Treatment of Influenza in Children

Influenza in Children
Public Health England

Completed

Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls (Flushed)

Influenza | Vaccination | Influenza Vaccination

United Kingdom
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Pantec Biosolutions AG
Medical University of Vienna

Completed

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Influenza in Human

Austria
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
David Scheifele
Canadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

H1N1/2009 Influenza

Canada
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
University of Nottingham

Completed

Virus Shedding and Environmental Deposition of a Novel Influenza Virus

Novel (H1N1) Influenza

United Kingdom
University of Manitoba
Hoffmann-La Roche

Terminated

Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU (ROSII)

Influenza A Virus

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Face Masks for Preventing Influenza Transmission (GRIPMASK)

Influenza Human

France
Taipei Medical University WanFang Hospital

Unknown

Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

H1N1 Influenza Virus

Taiwan
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

COVID-19 | Influenza A | Influenza B

United States
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

COVID-19 | Influenza A | Influenza Type B

United States
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Prevention of Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A Virus

United States, France, Belgium, Germany, Hong Kong, Spain, Malaysia, Turkey, Canada, Netherlands, Singapore, Brazil, New Zealand, Australia, Sweden
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Boston Medical Center

Completed

Impact of Rapid Flu Testing in BMC ED (FluProcess)

Influenza | Influenza-Like Illness

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

Prepandemic Influenza Vaccine

Hungary
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
Mexican Emerging Infectious Diseases Clinical Research...
National Institute of Allergy and Infectious Diseases (NIAID); Instituto Nacional... and other collaborators

Completed

Characterization of Influenza-like Illness in Mexico

Influenza-like Illness

Mexico
Green Cross Corporation

Completed

Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.

Prevention of Influenza
US Department of Veterans Affairs
St. Louis University

Withdrawn

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (CCTA #0005)

Aged | Influenza Vaccines

United States

3

Subscribe